文献速递脑血管病

替格瑞洛联合阿司匹林在急性缺血性卒中或短暂性脑缺血发作中的缺血获益与出血风险

Ischemic Benefit and Hemorrhage Risk of Ticagrelor-Aspirin Versus Aspirin in Patients With Acute Ischemic Stroke or Transient Ischemic Attack.
PubMed 文献 · Stroke · 2021-09-03

结果显示替格瑞洛联合阿司匹林组主要缺血事件绝对风险降低1.19%,主要出血绝对风险增加0.29%,净临床影响有利于替格瑞洛联合阿司匹林。

要点

  • 替格瑞洛联合阿司匹林30天治疗减少主要缺血事件,绝对风险降低1.19%。
  • 替格瑞洛联合阿司匹林增加主要出血风险,绝对风险增加0.29%。
  • 净临床影响有利于替格瑞洛联合阿司匹林,绝对风险降低0.97%。

核心结论

  • 在轻中度缺血性卒中或高危TIA患者中,30天替格瑞洛联合阿司匹林治疗的缺血获益超过出血风险。

主要发现

  • 主要缺血事件(缺血性卒中或非出血性死亡)在替格瑞洛联合阿司匹林组发生294例(5.3%),阿司匹林组359例(6.5%),绝对风险降低1.19%(95%CI 0.31%–2.07%)。
  • 主要出血(颅内出血或出血性死亡)在替格瑞洛联合阿司匹林组发生22例(0.4%),阿司匹林组6例(0.1%),绝对风险增加0.29%(95%CI 0.10%–0.48%)。
  • 净临床影响有利于替格瑞洛联合阿司匹林,绝对风险降低0.97%(95%CI 0.08%–1.87%)。

临床怎么用

  • 对于轻中度急性非心源性缺血性卒中或高危TIA患者,可考虑在症状出现24小时内启动30天替格瑞洛联合阿司匹林治疗以降低缺血事件风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: In patients with acute mild-moderate ischemic stroke or high-risk transient ischemic attack, the THALES trial (Acute Stroke or Transient Ischemic Attack Treated With Ticagrelor and Aspirin for Prevention of Stroke and Death) demonstrated that when added to aspirin, ticagrelor reduced stroke or death but increased risk of severe hemorrhage compared with placebo. The primary efficacy outcome of THALES included hemorrhagic stroke and death, events also counted in the primary safety outcome. We sought to disentangle risk and benefit, assess their relative impact, and attempt to identify subgroups with disproportionate risk or benefit. METHODS: In a randomized, placebo-controlled, double-blind trial of patients with mild-to-moderate acute noncardioembolic ischemic stroke or high-risk transient ischemic attack, patients were randomized within 24 hours after symptom onset to a 30-day regimen of either ticagrelor plus aspirin or matching placebo plus aspirin. For the present analyses, we defined the efficacy outcome, major ischemic events, as the composite of ischemic stroke or nonhemorrhagic death, and defined the safety outcome, major hemorrhage, as intracranial hemorrhage or hemorrhagic death. Net clinical impact was defined as the combination of these 2 end points. RESULTS: In 11 016 patients (5523 ticagrelor-aspirin and 5493 aspirin), a major ischemic event occurred in 294 patients (5.3%) in the ticagrelor-aspirin group and in 359 patients (6.5%) in the aspirin group (absolute risk reduction 1.19% [95% CI, 0.31%–2.07%]). Major hemorrhage occurred in 22 patients (0.4%) in the ticagrelor-aspirin group and 6 patients (0.1%) in the aspirin group (absolute risk increase 0.29% [95% CI, 0.10%–0.48%]). Net clinical impact favored ticagrelor-aspirin (absolute risk reduction 0.97% [95% CI, 0.08%–1.87%]). Findings were similar when different thresholds for disability were applied and over a range of predefined subgroups. CONCLUSIONS: In patients with mild-moderate ischemic stroke or high-risk transient ischemic attack, ischemic benefits of 30-day treatment with ticagrelor-aspirin outweigh risks of hemorrhage. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03354429.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Johnston SC, Amarenco P, Aunes M, et al. Ischemic Benefit and Hemorrhage Risk of Ticagrelor-Aspirin Versus Aspirin in Patients With Acute Ischemic Stroke or Transient Ischemic Attack. Stroke. 2021. PMID: 34477459. doi:10.1161/STROKEAHA.121.035555

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。